Mitoxantrone, etoposide, and cyclospine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia

Journal of Clinical Oncology

Volumn 18, Issue 9, 2000, Pages 1867-1875

  Dahl, Gary V ^a   Lacayo, Norman J ^a   Brophy, Nathalie ^a   Dunussi Joannopoulos, Kyriaki ^a   Weinstein, Howard J ^a   Chang, Myron ^a   Sikic, Branimir I ^a   Arceci, Robert J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; ANTINEOPLASTIC AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CARDIOTOXICITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SCHOOL CHILD; STOMATITIS; BLOOD; FLOW CYTOMETRY; GENE; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NEWBORN; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; GENES, MDR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MITOXANTRONE; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0033625107     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.9.1867     Document Type: Article

References (37)

1. Ebb DH, Weinstein HJ: Diagnosis and treatment of childhood acute myelogenous leukemia. Pediatr Clin North Am 44:847-862, 1997
2. Creutzig U, Ritter J, Schellong G: Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78, Blood 75:1932-1940, 1990
3. Ravindranath Y, Steuber CP, Krischer J, et al: High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A Pediatric Oncology Group study. J Clin Oncol 9:572-580, 1991
4. Wells RJ, Woods W, Lamphin B, et al: Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: A report from the Children's Cancer Group. J Clin Oncol 11:538-545, 1993
5. th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 89:2311-2318, 1997
6. Woods WG, Kobrinsky N, Buckley JD, et al: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 87:4979-4989, 1996
7. Stahnke K, Boos J, Bender-Gotze C, et al: Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 12:1534-1538, 1998
8. Marie JP, Zittoun R, Sikie BI: Multidrug resistance (MDR1) gene expression in adult acute leukemia: Correlation with treatment outcome and in vitro drug sensitivity. Blood 78:586-592, 1991
9. Pirker R, Wallner J, Geissler K, et al: MDR 1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708-712, 1991
10. Willman CL: Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: Significance of expression of the multidrug resistance gene-1 (MDR 1). Leukemia 1:S33-S35, 1996 (suppl)
11. Litman T, Zeuthern T, Skovsgaard T, et al: Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Am 1361:169-176, 1997
12. Fisher GA, Sikic BI: Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9:363-382, 1995
13. Beck WT, Grogan TM, Willman CL, et al: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 56:3010-3020, 1996
14. List AF, Kopecky KJ, Willman CL, et al: Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study. Blood 92:1998 (suppl 1, abstr 1281)
15. Advani R, Saba HI, Tallman MS, et al: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93:787-795, 1999
16. Ravindranath Y, Yeager AM, Chang MN, et al: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood: Pediatric Oncology Group. N Engl J Med 334:1428-1434, 1996
17. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
18. Arceci RJ, Stieglitz K, Bras J, et al: Monoclonal antibody to an external epitope of the human MDR 1 P-glycoprotein. Cancer Res 53:1-8, 1993
19. Leith CP, Chen IM, Kopecky KJ, et al: Correlation of multidrug resistance (MDR 1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identitication of discordant MDR-/efflux+ and MDR+/efflux-cases. Blood 86:2329-2342, 1995
20. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR 1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study. Blood 89:3323-3329, 1997
21. Ivy SP, Olshefski RS, Taylor BJ, et al: Correlation of P-glycoprotein expression and function in childhood acute leukemia: A Children's Cancer Group study. Blood 88:309-318, 1996
22. Pearson L, Leith CP, Duncan MH, et al: Multidrug resistance-1 (MDR 1) expression and functional dye/drug efflux is highly correlated with the t(8:21) chromosomal translocation in pediatric acute myeloid leukemia. Leukemia 10:1274-1282, 1996
23. Ino T, Miyazaki H, Isogai M, et al: Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: Results of molecular and functional assays, and correlation with treatment outcome. Leukemia 8:1492-1497, 1994
24. Noonan KE, Beck C, Holzmayer TA, et al: Quantitative analysis of MDR1 (multidrug resistance) gene in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 87:7160-7164, 1990
25. Mechetner EB, Roninson IB: Efficient inhibition of P-glycoprotein mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 89:5824-5828, 1992
26. Broxterman HJ, Sonneveld P, Feller N, et al: Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for P-glycoprotein expression and activity. Blood 87: 4809-4816, 1996
27. Broxterman HJ, Lankelma J, Pinedo HM, et al: Theoretical and practical considerations for the measurement of P-glycoprotein function in acute myeloid leukemia. Leukemia 11:1110-1118, 1997
28. Cornwell MM, Pastan I, Gottesman MM: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262:2166-2170, 1987
29. 3H]vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the MDR1 gene. Cancer Res 49:3867-3871, 1989
30. Arceci RJ, Stieglitz K, Bierer BE: Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80:1528-1536, 1992
31. Mantel N, Haenszel S: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
32. Lehmann EL: Statistical methods based on ranks, in Nonparametrics. San Francisco, CA, Holden-Day, 1975, p 316
33. Barnard DR, Kalousek DK, Wiersma SR, et al: Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: A report from the Children's Cancer Group. Leukemia 10:5-12, 1996
34. Lacayo NL, Lum B, Johnson S, et al: Pharmacokinetics of etoposide and mitoxantrone in a controlled trial of cyclosporine (CSA) as an MDR modulator in acute myeloid leukemia (AML) from the Pediatric Oncology Group (POG). Proc Am Soc Clin Oncol 16:514, 1997 (abstr 1850)
35. Ho AD, Lipp T, Ehninger G, et al: Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - an active and well-tolerated regimen. J Clin Oncol 6:213-217, 1988
36. Sievers EL, Smith FO, Woods WG, et al: Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: A report from the Children's Cancer Group. Leukemia 9:2042-2048, 1995
37. Beketic-Oreskovic L, Duran GE, Chen G, et al: Decreased mutation rate for doxorubicin resistance and suppression of MDR1 gene activation by PSC 833. J Natl Cancer Inst 87:1593-1602, 1995